Oculis Holding AG (OCS) EBIT (2022 - 2026)
Oculis Holding AG (OCS) posted quarterly EBIT of -$27.7 million for Q1 2026, down 24.89% year-over-year from -$36.9 million in Q1 2025, and down 7.48% quarter-over-quarter from -$25.8 million in Q4 2025.
Analysis
Oculis Holding AG (OCS) EBIT (2022 - 2026) Analysis & Trends
Oculis Holding AG's EBIT history runs 5 years deep, the most recent figure standing at -$27.7 million for Q1 2026.
- In Q1 2026, EBIT fell 24.89% year-over-year to -$27.7 million; the TTM figure through Mar 2026 stood at -$78.7 million (down 17.77% YoY), while the FY2025 annual figure was -$98.5 million, down 18.38% from the prior year.
- EBIT for Q1 2026 stood at -$27.7 million, down from -$25.8 million in the prior quarter.
- The five-year high for EBIT was -$20926.9 in Q3 2024, with the low at -$48.5 million in Q1 2023.
- The 5-year median for EBIT is -$16.1 million (2024), against an average of -$17.5 million.
- Peak annual rise in EBIT reached 99.86% in 2024, while the deepest fall reached 108.06% in 2024.
- Oculis Holding AG's EBIT stood at -$11.5 million in 2022, then retreated by 19.07% to -$13.7 million in 2023, then tumbled by 43.44% to -$19.7 million in 2024, then sank by 31.02% to -$25.8 million in 2025, then slipped by 7.48% to -$27.7 million in 2026.
- Business Quant data shows OCS's EBIT at -$27.7 million in Q1 2026, -$25.8 million in Q4 2025, and -$25372.2 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Oculis Holding AG | 634.75 Mn | 345.87 Mn | - | 392,224.12 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 392,224.12 |
| Mar 31, 2026 | 266,893.98 |
| Dec 31, 2025 | 514,230.78 |
| Sep 30, 2025 | 303,776.61 |
| Jun 30, 2025 | 315,259.35 |
| Mar 31, 2025 | 316,991.40 |
| Dec 31, 2024 | 3,424.57 |
| Sep 30, 2024 | 249,308.76 |
| Jun 30, 2024 | 270,919.40 |
| Mar 31, 2024 | 254,341.47 |
| Dec 31, 2023 | 208,560.58 |
| Sep 30, 2023 | 247,941.41 |
| Jun 30, 2023 | 278,043.89 |
| Mar 31, 2023 | 247,586.23 |
| Dec 31, 2022 | 222,136.69 |
| Sep 30, 2022 | 209,162.24 |
| Jun 30, 2022 | 265,803.01 |